ReviewIndian journal of orthopaedics2026
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Review in Indian journal of orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biologics or surgery for moderate knee osteoarthritis? a patient-centered framework for short-term relief and long-term outcomes.Journal of orthopaedic surgery and research · 2026Review
- Preoperative fructosamine is comparable to HbA1c as a short-term glycemic marker for predicting postoperative complications in orthopaedic surgery: A systematic review and meta-analysis.Journal of orthopaedics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are currently being utilized extensively to treat obesity and type 2 diabetes. Recent data suggest their broad applications in the field of orthopedics, due to their beneficial effects on bone metabolism, cartilage preservation, and surgical outcomes. The current scoping review attempts to thoroughly assess the role of GLP-1 RAs in orthopedic care by synthesizing the most recent data on their effects on bone health, cartilage preservation, arthroplasty outcomes, and spine surgery. Methods: A comprehensive scoping review was conducted in accordance with PRISMA-ScR guidelines. A systematic search of meta-analyses and systematic reviews of GLP-1 RAs in orthopedic-relevant outcomes, including orthopedic applications, was performed on three different databases (PubMed, Embase, and Scopus) on September 9, 2025, using specific keywords. Data on study design, population, intervention, comparator, and outcomes were extracted and narratively synthesized to draw conclusions. Results: Eight reviews assessed bone and fracture outcomes, showing that liraglutide reduced fracture risk and improved bone formation markers, while exenatide had mixed effects. Long-term GLP-1 RA use (> 52 weeks) improved lumbar spine and femoral neck bone mineral density (BMD) and reduced fracture incidence. Three reviews evaluated cartilage and joint outcomes, reporting slower cartilage loss, fewer knee surgeries, and symptomatic improvements, with semaglutide showing consistent pain relief and functional gains. In arthroplasty, GLP-1 RA use was associated with reduced periprosthetic joint infection and lower readmission rates, particularly in diabetic and obese patients. In spine surgery, evidence suggested potential reductions in pseudarthrosis but mixed findings for complications and readmissions. Conclusion: GLP-1 RAs demonstrate promise in bone health, cartilage preservation, and perioperative orthopedic outcomes. However, evidence remains limited by heterogeneity, short follow-up, and underrepresentation of non-diabetic populations. Graphical Abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.